Norma nacional de atención clínica del cáncer de próstata

Objectives

Bolivia’s National Clinical Care Standard for Prostate Cancer establishes a nationwide, comprehensive framework to reduce prostate-cancer morbidity and mortality through health promotion, prevention, early detection, diagnosis, treatment, palliative care, rehabilitation and follow-up. It standardises care across the National Health System within the Family, Community and Intercultural Health model and aims to improve quality of life for affected people.[1][2]

• Strengthen prevention and health promotion by addressing modifiable risk factors, including tobacco use, harmful alcohol consumption, physical inactivity, unhealthy diets, overweight and obesity.[3]
• Standardise early detection and clinical assessment, including symptom assessment, prostate-specific antigen testing, diagnostic examination, imaging, biopsy, histopathological confirmation, staging and risk classification.[2][4]
• Provide risk- and stage-appropriate treatment, encompassing active surveillance, surgery, radiotherapy, brachytherapy, androgen-deprivation therapy, systemic therapies, focal approaches where indicated, and management of recurrent, advanced and metastatic disease.[5][6][7]
• Deliver palliative and supportive care that prioritises symptom control, pain management, psychosocial, nutritional, family and social needs, preservation of function and quality of life.[8][9]
• Ensure universal application of the standard in public, short-term social-security and private health establishments throughout Bolivia.[1]
• Align prostate-cancer care with the Universal and Free Health System, which seeks universal, free, equitable, intercultural and participatory health care, including progressive comprehensive cancer care.[10]

Implementation

Implementation relies on an integrated, mandatory care pathway across primary, secondary and tertiary levels, coordinated through functional health-service networks and differentiated by each facility’s clinical resolution capacity. The approach links community engagement and prevention with referral, specialist diagnosis, multidisciplinary treatment, counter-referral, follow-up, palliative care and quarterly compliance review.[11][12][13]

• Coordinate public providers, short-term social security, private providers and traditional medicine through the National Health System, using available infrastructure, equipment, medicines and supplies according to the required level of care.[11]
• Promote awareness and early detection at the first level of care with community organisations; assess symptoms at first consultation, undertake prostate-specific antigen testing from age 40, refer suspected cases and train community health personnel.[2]
• Receive suspected cases at the second level for prostate-specific antigen testing, transabdominal ultrasound, and, where available or needed, transrectal assessment and biopsy; refer confirmed cancer to higher-complexity facilities and follow patients counter-referred after treatment.[2][14]
• Provide third-level laboratory, pathology, staging and multidisciplinary oncology services, including surgery, radiotherapy, hormonal therapy, chemotherapy, immunotherapy and targeted therapy; maintain follow-up, palliative care, quality control and professional updating.[14]
• Refer patients to higher-resolution facilities when the originating provider cannot resolve the clinical problem, transfer patients between services where appropriate, and counter-refer them to lower-level facilities after diagnosis or treatment for continuing follow-up.[11][12]
• Deliver specialised radiotherapy through multidisciplinary teams in centres with the required technology, physics expertise, organ-at-risk dose constraints and routine formal quality assurance.[6][15]
• Apply multidisciplinary care for advanced and castration-resistant disease, involving urologists, medical oncologists, radiation oncologists, nurses, psychologists and social workers, while considering palliative needs before further systemic treatment.[16][7]
• Use telehealth for selected assessment and follow-up activities where access to referral services is difficult, provided an in-person consultation is not required.[9]
• Engage communities, families and social organisations in health management through the Family, Community and Intercultural Health model, supported by institutional, social and intersectoral structures at national, departmental, municipal and local levels.[17][10]
• Oversee private-sector compliance with governing-body standards and have the Authority for Supervision of Short-Term Social Security safeguard cancer-related benefits for insured people and beneficiaries.[1]
• Review compliance quarterly through service chiefs, medical chiefs, establishment directors or designated responsible officers, using random samples of care delivered in the preceding quarter and scheduling the activity through the Annual Operating Plan.[13]
• Produce objective compliance reports that identify deficiencies and propose continuous-improvement actions; use data-collection tools and specific indicators to set targets and compare performance between health establishments.[13]
• Monitor clinical care through diagnostic-result management, histopathological confirmation, staging, treatment follow-up, counter-referral, prostate-specific antigen assessment where relevant, imaging and toxicity or complication review.[14][18]

Monitoring & Evaluation

The National Clinical Care Standard for Prostate Cancer combines service-compliance review, clinical follow-up, cancer epidemiology, diagnostic and pathological reporting, treatment-specific monitoring and participatory accountability. It provides the clearest programme-level audit mechanism through quarterly review of care delivered across the National Health System.[13]

• Review compliance quarterly through the service chief, medical chief, establishment director or responsible officer, using a random sample of care delivered in the preceding quarter and scheduling the activity in the Annual Operating Plan.[13]
• Produce objective summary reports on non-compliance and concrete continuous-improvement actions, using data-collection tools and specific indicators to establish strategies, targets and comparisons between establishments.[13]
• Assess compliance with diagnostic criteria, complementary examinations, differential diagnosis, complication management, treatment, referral, transfer, discharge, counter-referral, prevention and health-promotion measures.[13]
• Use referral, transfer and counter-referral to support continuity of care, including follow-up of disease progression after patients return to lower-complexity facilities.[19][11]
• Apply standardised documentation and classification, including TNM staging, prostate-specific antigen, International Society of Urological Pathology Grade Group, Gleason score, biopsy-core findings and pathological reporting parameters.[4][20][21][22]
• Maintain follow-up and monitoring of treated and counter-referred patients, including timely communication of diagnostic and histopathology results, clinical-surgical staging, quality control and staff updating at the third level of care.[14]
• Use active-surveillance follow-up, where clinically appropriate, with clinical examination, prostate-specific antigen testing, repeat biopsy and multiparametric magnetic resonance imaging; watchful waiting remains symptom-guided and individualised.[23]
• Monitor treatment-specific clinical measures, including testosterone suppression during androgen-deprivation therapy, liver enzymes for antiandrogen-related hepatotoxicity, pain intensity, bone complications, toxicity and quality of life.[24][25][26]
• Review advanced castration-resistant disease regularly through clinical assessment, prostate-specific antigen, blood tests every two to three months, and bone scintigraphy and computed tomography at least every six months; avoid stopping treatment on prostate-specific antigen progression alone.[18]
• Monitor recurrence after primary treatment through prostate-specific antigen every three months, chest radiography and abdominal ultrasound every six months, and bone scanning and tomography annually.[27]

National Cancer Registry and National Programme for Comprehensive Cancer Control data provide epidemiological surveillance context, including 48,084 new cancer cases recorded between 2016 and 2020 and 3,001 new prostate-cancer cases.[28][29][30]The source attributes lower recorded case totals in 2020 partly to the COVID-19 pandemic and under-registration during the health emergency.[28][30]

At sector level, intended results include reducing communicable and non-communicable diseases through prevention and promotion, increasing access to the Universal and Free Health System, and measuring the number of normative cancer-care documents developed and published.[31][32]Participatory health management through communities, health councils, assemblies and local authorities provides a social-accountability dimension, although formal reporting schedules, surveillance targets and wider accountability procedures are not fully specified.[17][10]

Costing & Financing

The material establishes a policy context of universal and free public health care, including progressive comprehensive cancer care, but does not provide a national prostate-cancer budget, programme costing, allocation, financing gap, reimbursement arrangement, resource-mobilisation target or economic evaluation.[33][10][1]

• Provide services through the Unified Health System and the Universal and Free Health System, within public policies implemented across levels of government.[31][10]
• Use available infrastructure, equipment, medicines and supplies according to each facility’s resolution capacity within the Functional Health Services Network.[11]
• Recognise specialised resource requirements for radiotherapy, including multidisciplinary teams, specialised centres, inverse-planning computer systems, physics expertise, image guidance and formal quality assurance.[6][15]
• Recognise that hypofractionated radiotherapy reduces treatment time from approximately 38 to 20 sessions, offering a practical benefit to patients, health systems and radiotherapy services without a stated monetary valuation.[15][34]
• Consider treatment cost and adherence when choosing between medical and surgical castration, while noting that no quantified costs or funding gap are provided.[24]
• Recognise considerable costs associated with agents demonstrating overall-survival benefit in advanced castration-resistant prostate cancer, without stated prices, financing sources or budget allocations.[18]
• Note supply and access constraints where technologies or medicines are unavailable locally, including fusion biopsy technology, some androgen-receptor agents and domestically produced prostate-specific membrane antigen radiopharmaceuticals.[35][36][37]

Across prevention, diagnostic services, surgery, radiotherapy, systemic treatment, palliative care and follow-up, the excerpts do not specify unit costs, workforce costings, capital-investment requirements, medicine prices, funding sources or an affordability assessment.[1][6][18][27]